CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer

被引：7
作者：
Allen, Clint T. [1 ]
Conley, Barbara [2 ]
Sunwoo, John B. [3 ]
Van Waes, Carter [1 ]
机构：
[1] NIDCD, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Canc Diag Program, NIH, Bethesda, MD 20892 USA
[3] Stanford Univ, Sch Med, Dept Otolaryngol, Div Head & Neck Surg, Stanford, CA 94305 USA
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 05期
关键词：
FACTOR-KAPPA-B; SQUAMOUS-CELL CARCINOMA; TARGET;
D O I：
10.1158/1078-0432.CCR-14-2550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In a study published in the May 1, 2001, issue of Clinical Cancer Research, Sunwoo and colleagues provided evidence for proteasome inhibition of NF-kappa B and tumorigenesis, supporting early-phase clinical trials in solid malignancies of the upper aerodigestive tract. Subsequent clinical studies uncovered a dichotomy of responses in patients with hematopoietic and solid malignancies, and the mechanisms of resistance. (C) 2015 AACR.
引用
收藏
页码：942 / 943
页数：2
相关论文
共 10 条
  • [1] Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-κB subunits in head and neck cancer
    Allen, Clint
    Saigal, Kunal
    Nottingham, Liesl
    Arun, Pattatheyil
    Chen, Zhong
    Van Waes, Carter
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (13) : 4175 - 4185
  • [2] [Anonymous], SEMIN HEMATOL
  • [3] Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
    Argiris, Athanassios
    Duffy, Austin G.
    Kummar, Shivaani
    Simone, Nicole L.
    Arai, Yoshio
    Kim, Seungwon W.
    Rudy, Susan F.
    Kannabiran, Vishnu R.
    Yang, Xinping
    Jang, Minyoung
    Chen, Zhong
    Suksta, Nanette
    Cooley-Zgela, Theresa
    Ramanand, Susmita G.
    Ahsan, Aarif
    Nyati, Mukesh K.
    Wright, John J.
    Van Waes, Carter
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (17) : 5755 - 5764
  • [4] Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms
    Chen, Zhong
    Ricker, Justin L.
    Malhotra, Pramit S.
    Nottingham, Liesl
    Bagain, Lorena
    Lee, Tin Lap
    Yeh, Ning T.
    Van Waes, Carter
    [J]. MOLECULAR CANCER THERAPEUTICS, 2008, 7 (07) : 1949 - 1960
  • [5] NF-κB and the link between inflammation and cancer
    DiDonato, Joseph A.
    Mercurio, Frank
    Karin, Michael
    [J]. IMMUNOLOGICAL REVIEWS, 2012, 246 : 379 - 400
  • [6] The Immunoproteasome as a Target in Hematologic Malignancies
    Kuhn, Deborah J.
    Orlowski, Robert Z.
    [J]. SEMINARS IN HEMATOLOGY, 2012, 49 (03) : 258 - 262
  • [7] Bortezomib: Understanding the Mechanism of Action
    Piperdi, Bilal
    Ling, Yi-He
    Liebes, Leonard
    Muggia, Franco
    Perez-Soler, Roman
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (11) : 2029 - 2030
  • [8] Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419
  • [9] Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma
    Van Waes, C
    Chang, AA
    Lebowitz, PF
    Druzgal, CH
    Chen, Z
    Elsayed, YA
    Sunwoo, JB
    Rudy, SF
    Morris, JC
    Mitchell, JB
    Camphausen, K
    Gius, D
    Adams, J
    Sausville, EA
    Conley, BA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (05): : 1400 - 1412
  • [10] Targeting NF-κB in Mouse Models of Lung Adenocarcinoma
    Van Waes, Carter
    [J]. CANCER DISCOVERY, 2011, 1 (03) : 200 - 202
1